Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
AS210006-A08
Phase 1 small_molecule active
Quick answer
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg for Alcohol Use Disorder (AUD) is a Phase 1 program (small_molecule) at BioXcel Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BioXcel Therapeutics
- Indication
- Alcohol Use Disorder (AUD)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active